Edwards Lifesciences Corporation (NYSE: EW), a medical device maker specializing in structural heart therapies such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid valve repair, has drawn a wave of constructive analyst commentary over the past year. The question facing investors is whether the stock, recently trading near $87, can climb to a round-number milestone of $100.
Across the roughly 29 to 30 analyst targets reviewed, the arithmetic mean sits near $101 to $102, which we round to a clean $100 central target. The range is unusually wide, from about $84 at the low end to $110 at the high end, reflecting genuine disagreement about how quickly Edwards can re-accelerate growth.
Recent revisions have leaned constructive. UBS upgraded the shares to Buy from Neutral with a $110 target in July 2026, while BTIG, Barclays, Citi, and RBC Capital have each carried $110 targets into October 2026. Jefferies has maintained a $105 target, and Goldman Sachs and Stifel have held targets near $105 to $108. On the more cautious side, Truist lowered its target to $89 in February 2026, and several firms hold Hold-equivalent ratings with targets in the high $80s to mid $90s.
Notably, the average analyst price target is not a guarantee. The bullish camp points to TAVR indication expansion and structural heart pipeline durability, while the cautious camp argues that much of the 2026 outlook is already reflected in the share price and that execution and competitive risks remain.
Edwards Lifesciences trades at roughly $87.22, giving it a market capitalization near $50 billion. Its 52-week range spans $74.43 to $96.29, meaning the stock is already well off its lows but still below its 52-week high. Reaching the $100 target would require a gain of about 15% from current levels, which represents a substantial move for a large-cap medical device name.
The path toward $100 would likely require the stock to first clear its 52-week high near $96 and then hold above that level. Fundamentally, such a move would depend on continued double-digit TAVR procedure growth, successful commercialization of the newly approved SAPIEN M3 mitral valve replacement system, and evidence that the 2026 financial framework is tracking ahead of expectations.
Several verified factors underpin the constructive analyst price forecast. Edwards guided to 8% to 10% full-year 2026 sales growth and EPS (earnings per share) of roughly $2.90 to $3.05, supported by resilient TAVR demand. The U.S. FDA approval of the SAPIEN M3 transcatheter mitral valve replacement system broadens Edwards' addressable market, while seven-year PARTNER 3 durability data reinforce confidence in the flagship TAVR franchise.
Analysts also cite the EVOQUE tricuspid replacement system and planned expansion into left atrial appendage closure as incremental growth drivers. Several firms, including TD Cowen, UBS, and J.P. Morgan, have upgraded the shares in the past year, and the stock's forward P/E (price-to-earnings) multiple near the high 20s leaves room for multiple expansion if earnings momentum accelerates.
The principal obstacle is valuation and the limited flow-through of revenue beats to EPS, a point Truist flagged when it trimmed its target. The Federal Trade Commission successfully blocked Edwards' proposed acquisition of JenaValve Technology, removing a near-term catalyst and leaving the company to advance its SOJOURN aortic regurgitation program organically.
Competitive pressure from peers such as Boston Scientific and Abbott, policy uncertainty around Medicare and the Affordable Care Act, and the risk that procedure volumes normalize remain live concerns. If execution stumbles or multiple compression occurs, the stock could struggle to break decisively above its 52-week high.
The most relevant technical marker is the 52-week high of $96.29, set in July 2026. That zone represents resistance that must be cleared before the round-number $100 level comes into view. On the downside, the stock has held support in the mid-$80s, with the 52-week low of $74.43 acting as a longer-term floor. A decisive move above $96, sustained over multiple sessions, would be a meaningful structural signal in the context of this $100 price target.
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms apply differing assumptions. Investors should watch upcoming quarterly earnings and guidance updates, particularly any revision to the 2026 sales and EPS outlook, as well as TAVR procedure trend commentary and commercial updates on SAPIEN M3 and EVOQUE. Regulatory and reimbursement decisions, competitive launches, and any shift in analyst revisions will also matter for the trajectory toward $100.
For traders seeking a more systematic way to track changing conditions, Tickeron's AI Daily Buy/Sell Signals offer an artificial intelligence-driven approach. The tool continuously monitors thousands of stocks and ETFs and generates Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Traders can use it to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. Explore the AI Daily Buy/Sell Signals to see how they might complement your own research process.
The $100 target is a reasonable expression of the average analyst price target for Edwards Lifesciences, implying roughly 15% upside from current levels. It is supported by a durable TAVR franchise, an expanding structural heart portfolio, and firm 2026 guidance, yet it faces real obstacles in the form of valuation, competition, and the loss of the JenaValve catalyst. With targets spanning $84 to $110, the analyst consensus reflects meaningful disagreement rather than certainty. Whether EW reaches $100 will ultimately depend on sustained procedure growth, successful new product launches, and investors' willingness to pay a premium multiple. No outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, EW has been loosely correlated with ISRG. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if EW jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To EW | 1D Price Change % |
|---|---|---|
| EW | 100% | +0.12% |
| Health Services category (240 stocks) | 6% Poorly correlated | -0.29% |
| Medical/Nursing Services category (139 stocks) | 5% Poorly correlated | -0.10% |